Drug – bio-affecting and body treating compositions – Antigen – epitope – or other immunospecific immunoeffector – Fusion protein or fusion polypeptide
Reexamination Certificate
2007-04-10
2007-04-10
Yaen, Christopher H. (Department: 1643)
Drug, bio-affecting and body treating compositions
Antigen, epitope, or other immunospecific immunoeffector
Fusion protein or fusion polypeptide
C424S185100, C424S195110
Reexamination Certificate
active
09815306
ABSTRACT:
A novel fusion protein, comprising a receptor-antagonizing domain and a positive immunomodulator domain, characterized, for example, by its ability to block apoptosis and/or inhibit endocrine response, is useful in treating cancer. For example, a human prolactin antagonist-interleukin 2 (hPRLA-IL-2) fusion protein combines apoptosis induction and immuno-therapy to combat cancer in the breast or prostate.
REFERENCES:
patent: 5314995 (1994-05-01), Fell et al.
patent: 6429186 (2002-08-01), Fuh et al.
patent: WO 98/08949 (1998-03-01), None
patent: WO 99/58142 (1999-11-01), None
Macieira-Coelho A Biogerontology 2001;2(3):179-92.
Mocellin S et al. J. Immunother Sep.-Oct. 2001; 25(5):392-407.
Lode et al. Proc Natl Acad Sci USA Feb. 1999; 96(4):1591-1596.
Gillies et al. J. Immuno 1998; 160(12):6195-203.
Bulfone-Paus S et al. Transplantation 2000 Spr 15;69(7):1386-91.
Sissom et al (Am J. Pathol. 1988;133(3):589-95).
Gillies et al (J. Immunology, 1998;160(12):6195-6203).
Gura (Science, v278, 1997, pp. 1041-1042).
Kelly et al (Mol. Cell. Endocrinology 2002;197:127-131).
Rozengurt (Curr. Opin. Oncology 1999;11(2):116).
Jones et al (Leuk Lymphoma. Jun. 2002;43(6):1313-21).
Biology of Female Cancers, CRC Press LLC, pp. 31-42, 1997.
Cleveenger et al., “Expression of Prolactin and Prolactin Receptor in Human Breast Carcinoma”, American Journal of Pathology, American Society for Investigative Pathology, vol. 146, No. 3, pp. 695-705, Mar. 1995.
Ginsburg et al., “Prolactin Synthesis and Secretion by Human Breast Cancer Cells”; Cancer Research, An Official Journal of the American Association for Cancer Research, vol. 55, No. 12, pp. 2591-2595, Jun. 15, 1995.
Wnnbo et al., “Transgenic Mice Overexpressing the Prolactin Gene Develop Dramatic Enlargement of the Prostate Gland”, Endocrinology, The Endocrine Society, vol. 38, No. 10, pp. 4410-4415, Oct. 1997.
Aragona et al, “Specific Prolactin Binding Sites in the Prostate and Testis of Rats”, Endocrinology, The Endocrine Society, vol. 97, No. 3, pp. 677-684, Sep. 1975.
Leake et al., “Characterization of the Prolactin Receptor in Human Prostate”; The Journal of Endocrinology, The Journal of Endocrinology Limited, vol. 99, No. 2, pp. 321-328, Nov. 1983.
Hammond et al., “Serum FSH, LH and Prolactin in Normal Males and Patients with Prostatic Diseases”, Clinical Endocrinology, Blackwell Scientific Publications, vol. 7, No. 2, pp. 129-135, Aug. 1977.
“Influence of Age on Serum Prolactin Levels in Women and Men”, British Medical Journal, vol. 4, No. 5999, pp. 738-739, Dec. 27, 1975.
Boon., “Toward a Genetic Analysis of Tumor Rejection Antigens”, Advances in Cancer Research, Academic Press, Inc., vol. 58, pp. 177-210, 1992.
Urban et al., “Tumor Antigens”, Annual Review of Immunology, Annual Reviews Inc., vol. 10, pp. 617-644, 1992.
“Selective in Vitro Growth of T Lymphocytes from Normal Human Bone Marrows”, Science, American Association for the Advancement of Science, vol. 193, No. 4257, pp. 1007-1008, Sep. 10, 1976.
Hendrzak et al., “Interferons and Other Cytokines”, Cancer Therapeutics, Human Press, pp. 263-282, 1997.
Rosenberg et al., “Use of Tumor Infiltrating Lymphocytes and Interleukin-2 in the Immunotherapy of Patients with Metastaic Melanoma”, The New England Journal of Medicine, The Massachusetts Medical Society, vol. 319, No. 25, pp. 1676-1680, Dec. 22, 1988.
Maas et al., “Transfer of Tumor Immunity by Both CD4+and DC8+Tumor Infiltrating T Lymphocytes Activatedin vivoby IL-2 Therapy of Tumor Bearing Mice”, Immunobiology, vol. 188, Mo. 3, pp. 281-292, 1993.
Forni et al., “Interleukin 2 Activated Tumor Inhibition in Vivo Depends on the Systemic Involvement of Host Immunoreactivity”, Journal of Immunology, The American Society of Immunologists, vol. 138, No. 11, pp. 4033-4041, Jun. 1, 1987.
Fearon et al., “Interleukin-2 Production by Tumor Cells Bypasses T Helper Function in the Generation of an Antitumor Response”, Cell, Cell Press, vol. 60, No. 3, pp. 397-403, Feb. 9, 1990.
Pardoll, “Cancer Vaccines”, Immunology Today, Elsevier Science Publishers Ltd., vol. 14, No. 6, pp. 310-316, 1993.
Reisfeld et al., “Recombinant Antibody Fusion Proteins for Cancer Immunotherapy”, Attempts to Understand Metastasis Formation III, Springer, pp. 28-53, 1996.
Gillies et al., “Antibody-Targeted Interleukin 2 Stimulates T-Cell Killing of Autologous Tumor Cells”, Immunology, Proceedings of the National Academy of Sciences, of the United States of America, vol. 89, No. 4, pp. 1428-1432, Feb. 1992.
Sabzevari et al., “ A Recombinant Antibody-Interleukin 2 Fusion Protein Suppresses Growth of Hepatic Human Neuroblastoma Metastases in Severe Combined Immunodeficiency Mice”, Immunology, Proceedings of the National Academy of Sciences, of the United States of America, vol. 91, No. 20, pp. 9626-9630, Sep. 1994.
Chen et al., “A Human Prolactin Antagonist, hPRL-G129R, Inhibits Breast Cancer Cell Proliferation through Induction of Apoptosis”, Clinical Cancer Research, vol. 5, No. 11, pp. 3583-3593, Nov. 1999.
Herbert et al., “Chelerythrine is a Potent and Specific Inhibitor of Protein Kinase C”, Biochemical and Biophysical Research Communications, Academic Press, Inc., vol. 172, No. 3, pp. 993-999, Nov. 15, 1990.
Paris et al., “Bacterial Production and Purification of Recombinant Human Prolactin”, Biotechnology and Applied Biochemistry, Academic Press, Inc., vol. 12, No. 4, pp. 436-449, 1990.
Gluzman, “SV40-Transformed Simian Cells Support the Replication of Early SV40 Mutants”, Cell, MIT, vol. 23, No. 1, pp. 175-182, Jan. 1981.
Logan et al., “Adenovirus Tripartite Leader Sequence Enhances Translation of mRNAs Late After Infection”, Biochemistry, Proceedings of the National Academy of Sciences of the United States of America, vol. 81, No. 12, pp. 3655-3659, Jun. 1984.
Chen et al., “Expression of a Mutated Bovine Growth Hormone Gene Suppresses Growth of Transgenic Mice”, Cell Biology, Proceedings of the National Academy of Sciences of the United States of America, vol. 87, No. 13, pp. 5061-5065, Jul. 1990.
Reynolds et al., “Expression of Prolactin and Its Receptor in Human Breast Carcinoma”, Endocrinology, The Endocrine Society, vol. 138, No. 12, pp. 5555-5560, Dec. 1997.
Sirbsku et al., “Estrogen Mitogenic Action, IL Negative Regulation of the Steroid Hormone-Responsive Growth of Cell Lines Derived from Human and Rodent Target Tissue Tumors and Conceptual Implications”, Journal of the Society for In Vitro Biology, Invitro, vol. 36, No. 7, pp. 428-446, Jul.-Aug. 2000.
Sirbasku, “Estrogen Induction of Growth Factors Specific for Hormone-Responsive Mammary, Pituitary, and Kidney Tumor Cells”, Cell Biology, Proceedings of the National Academy of Sciences of the United States of America, vol. 75, No. 8, pp. 3786-3790, Aug. 1978.
Chen et al., “Amino Acid Residues in the Third α-Helix of Growth Hormone Involved in Growth Promoting Activity”, Molecular Endocrinology, the Endocrine Society, vol. 9, No. 3, pp. 292-302, 1995.
Dickson et al., “Hormonal Control of Human Breast Cancer Cell Lines”, Cancer Surveys, Imperial Cancer Research Fund, vol. 5, No. 3, pp. 617-624, 1986.
Bole-Feysot, et al.; Prolactin (PRL) and Its Receptor: Actions, Signal Transduction Pathways and Phenotypes Observed in PRL Receptor Knockout Mice; Endocrine Reviews 19(3): 225-268; 1998 by The Endocrine Society.
Harvey, Stephen et al., “Growth Hormone,” CRC Press, 1995, pp. 7-8.
R.A. Reisfeld et al., “Recombinant Antibody Fusion Proteins for Cancer Immunotherapy,”Current Topics in Microbiology and Immunology(1996), 213(3):27-53, XP001030927.
Chen Wen Y.
Wagner Thomas E.
Foley & Lardner LLP
Greenville Hospital System
Yaen Christopher H.
LandOfFree
Bi-functional cancer treatment agents does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Bi-functional cancer treatment agents, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Bi-functional cancer treatment agents will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3794234